Benzinga
Published Apr 23, 2024 16:00
Updated Apr 23, 2024 17:10
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Merck & Co (NYSE:MRK) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
Merck & Co Background Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Merck & Co Inc | 906.71 | 8.56 | 5.38 | -3.11% | $-0.77 | $10.72 | 5.78% |
Eli Lilly and Co | 126.09 | 64.55 | 19.36 | 19.91% | $3.03 | $7.57 | 28.1% |
Novo Nordisk A/S | 47.09 | 36.71 | 16.97 | 22.01% | $28.51 | $55.85 | 36.95% |
AstraZeneca PLC | 36.81 | 5.55 | 4.78 | 2.52% | $2.18 | $9.72 | 7.29% |
Novartis AG | 23.20 | 4.17 | 4.26 | 19.99% | $4.18 | $8.75 | 7.39% |
Pfizer Inc | 70.97 | 1.67 | 2.53 | -3.62% | $-1.77 | $6.69 | -41.34% |
Sanofi SA | 20.56 | 1.49 | 2.39 | -0.75% | $0.42 | $8.15 | 6.5% |
Bristol-Myers Squibb Co | 12.73 | 3.38 | 2.27 | 6.03% | $4.45 | $8.73 | 0.62% |
GSK PLC | 13.69 | 5.02 | 2.22 | 2.64% | $1.16 | $5.63 | 9.16% |
Zoetis Inc | 28.71 | 13.31 | 7.87 | 10.42% | $0.83 | $1.49 | 8.48% |
Takeda Pharmaceutical Co Ltd | 36.74 | 0.96 | 1.57 | 1.53% | $314.89 | $731.71 | 1.33% |
Viatris Inc | 225 | 0.65 | 0.88 | -3.7% | $-0.07 | $1.6 | -1.0% |
Dr Reddy's Laboratories Ltd | 19.24 | 3.75 | 3.70 | 5.29% | $22.42 | $42.2 | 6.57% |
Jazz Pharmaceuticals PLC | 17.83 | 1.81 | 2.04 | 2.61% | $0.29 | $0.9 | 4.1% |
Average | 52.2 | 11.0 | 5.45 | 6.53% | $29.27 | $68.38 | 5.7% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } By analyzing Merck & Co, we can infer the following trends:
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Merck & Co can be assessed by comparing it to its top 4 peers, resulting in the following observations:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.